CeraVx B.V. is a privately held global biotechnology company based in the Netherlands developing and commercializing a proprietary drug delivery platform based on ceramic micro-needle array patches (CeraMAPs™). The CeraMaps technology was initially developed at the University of Twente, MESA+, Institute for Nanotechnology, The Netherlands. In 2024 CeraVx acquired the proprietary micro-needle technology from MLT. The company is focussing on intradermal delivery of prophylactic and therapeutic vaccines.